All In Biotech

Drug Trial Radar · NCT05382338

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Feb 20, 2023

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effective at treating the cancer, there are still concerns about the side effects of such treatment. Side effects or unintended health conditions that arise due to treatment include learning difficulties, hearing loss or other issues in performing daily activities. Standard therapy for newly diagnosed average-risk or low-risk medulloblastoma includes surgery, radiation therapy, and chemotherapy (including cisplatin). Cisplatin may cause hearing loss as a side effect. In the average-risk medulloblastoma patients, this trial tests whether the addition of sodium thiosulfate (STS) to standard of care chemotherapy and radiation therapy reduces hearing loss. Previous studies with STS have shown that it may help reduce or prevent hearing loss caused by cisplatin. In the low-risk medulloblastoma patients, the study tests whether a less intense therapy (reduced radiation) can provide the same benefits as the more intense therapy. The less intense therapy may cause fewer side effects. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. The overall goals of this study are to see if giving STS along with standard treatment (radiation therapy and chemotherapy) will reduce hearing loss in medulloblastoma patients and to compare the overall outcome of patients with medulloblastoma treated with STS to patients treated without STS on a previous study in order to make sure that survival and recurrence of tumor is not worsened.

Conditions

  • Childhood Medulloblastoma

Interventions

  • Audiometric TestProcedure

    Ancillary studies

  • Auditory Brainstem ResponseProcedure

    Ancillary studies

  • Biospecimen CollectionProcedure

    Undergo CSF and blood sample collection

  • CisplatinDrug

    Given IV

  • CyclophosphamideDrug

    Given IV

  • LomustineDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo radiation therapy

  • Sodium ThiosulfateDrug

    Given IV

  • Survey AdministrationOther

    Ancillary studies

  • VincristineDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with >= grade 2 hearing lossTime frame: At 4 weeks after the last dose of cisplatin
  2. Event-free survival (EFS)Time frame: From initiation of the protocol treatment to the occurrence of disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm, assessed up to 10 years

Locations

111 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama · Active not recruiting

  • USA Health Strada Patient Care Center

    Mobile, Alabama · Recruiting

  • Phoenix Childrens Hospital

    Phoenix, Arizona · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Loma Linda University Medical Center

    Loma Linda, California · Recruiting

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California · Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Valley Children's Hospital

    Madera, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Children's Hospital of Orange County

    Orange, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Rady Children's Hospital - San Diego

    San Diego, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Connecticut Children's Medical Center

    Hartford, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida · Recruiting

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida · Recruiting

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • Nemours Children's Hospital

    Orlando, Florida · Recruiting

  • Nemours Children's Clinic - Pensacola

    Pensacola, Florida · Recruiting

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida · Recruiting

  • Saint Joseph's Hospital/Children's Hospital-Tampa

    Tampa, Florida · Recruiting

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • University of Illinois

    Chicago, Illinois · Recruiting

  • OSF Children's Hospital of Illinois

    Peoria, Illinois · Recruiting

  • Southern Illinois University School of Medicine

    Springfield, Illinois · Recruiting

  • Riley Hospital for Children

    Indianapolis, Indiana · Recruiting

  • Blank Children's Hospital

    Des Moines, Iowa · Recruiting

  • University of Iowa/Holden Comprehensive Cancer Center

    Iowa City, Iowa · Recruiting

  • Norton Children's Hospital

    Louisville, Kentucky · Recruiting

  • Children's Hospital New Orleans

    New Orleans, Louisiana · Recruiting

  • Sinai Hospital of Baltimore

    Baltimore, Maryland · Recruiting

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.